Combination of cholecalciferol derivatives for the treatment of renal bone disease

US4997824A · kind A · utility

Assignee

• TEVA PHARMACEUTICAL INDUSTRIES, LTD. · IL

Inventors

• Mordecai Popovtzer · Tveria, IL
• Ben Z. Weiner · 'Anata, IL
• Shmuel Edelstein · Rehovot, IL
• Zeev Mazor · 'Anata, IL
• David Ladkani · Kiryat Shmona, IL
• Benjamin Shalita · Netivot, IL
• John Kanis · Brussels, BE

Key dates

• Filing date: Jul 22, 1987
• Grant date: Mar 5, 1991
• Expiry date: Jul 22, 2007

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method and composition for an improved treatment of human renal osteodystrophy, comprising the administration of 6-40 mcg/d (micrograms per day) of 24,25(OH).sub.2 D.sub.3 in combination with amounts of 1-alpha(OH)D.sub. 3 or 1,25(OH).sub.2 D.sub.3 or DHT.sub.2, which will maintain in the serum of patients the calcium concentration at 10-11 mg/dl (milligrams per deciliter) and the phosphate concentration at 5.5-6.0 mg/dl (milligrams per deciliter) and the numerical multiplication product of calcium x phosphate not more than 60-65.